All In Biotech

Drug Trial Radar · NCT02187471

Treatment of Pain Associated With Fibromyalgia

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,301

Actual

Start

Jan 16, 2015

Primary completion

Jan 6, 2017

Study completion Jan 12, 2017

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Jul 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.

Conditions

  • Pain Associated With Fibromyalgia

Interventions

  • DS-5565Drug

    DS-5565 15 mg QD or BID; tablet for oral use

  • PregabalinDrug

    Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule

  • Placebo tabletDrug

    Placebo tablet for oral use, matching DS-5565 tablet

  • Placebo capsuleDrug

    Placebo capsule for oral use, matching pregabalin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or PlaceboTime frame: Baseline up to Week 13 postdose

Locations

154 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Covina, California

  • Site not named

    El Cajon, California

  • Site not named

    Encino, California

  • Site not named

    Huntington Beach, California

  • Site not named

    Lakewood, California

  • Site not named

    Lomita, California

  • Site not named

    Los Angeles, California

  • Site not named

    National City, California

  • Site not named

    Northridge, California

  • Site not named

    Oceanside, California

  • Site not named

    Sacramento, California

  • Site not named

    Upland, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Boca Raton, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Edgewater, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Largo, Florida

  • Site not named

    Lauderdale Lakes, Florida

  • Site not named

    Maitland, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Tamarac, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Winter Haven, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Dawsonville, Georgia

  • Site not named

    Marietta, Georgia

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.